Free Trial

Rein Therapeutics (RNTX) Competitors

Rein Therapeutics logo
$1.46 +0.04 (+2.82%)
As of 03:59 PM Eastern

RNTX vs. MCRB, ACTU, TARA, ONCY, PLX, SKYE, CTOR, BHST, ATOS, and HURA

Should you be buying Rein Therapeutics stock or one of its competitors? The main competitors of Rein Therapeutics include Seres Therapeutics (MCRB), Actuate Therapeutics (ACTU), Protara Therapeutics (TARA), Oncolytics Biotech (ONCY), Protalix BioTherapeutics (PLX), Skye Bioscience (SKYE), Citius Oncology (CTOR), BioHarvest Sciences (BHST), Atossa Genetics (ATOS), and TuHURA Biosciences (HURA). These companies are all part of the "pharmaceutical products" industry.

Rein Therapeutics vs. Its Competitors

Rein Therapeutics (NASDAQ:RNTX) and Seres Therapeutics (NASDAQ:MCRB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

In the previous week, Seres Therapeutics had 2 more articles in the media than Rein Therapeutics. MarketBeat recorded 3 mentions for Seres Therapeutics and 1 mentions for Rein Therapeutics. Rein Therapeutics' average media sentiment score of 1.89 beat Seres Therapeutics' score of 1.25 indicating that Rein Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Rein Therapeutics Very Positive
Seres Therapeutics Positive

Seres Therapeutics has higher revenue and earnings than Rein Therapeutics. Seres Therapeutics is trading at a lower price-to-earnings ratio than Rein Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Rein TherapeuticsN/AN/A-$62.88M-$2.86-0.51
Seres Therapeutics$126.32M1.00$140K-$4.60-3.16

Rein Therapeutics' return on equity of -86.07% beat Seres Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Rein TherapeuticsN/A -86.07% -31.11%
Seres Therapeutics N/A -41,084.76%-55.87%

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 59.3% of Seres Therapeutics shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by company insiders. Comparatively, 4.7% of Seres Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Rein Therapeutics has a beta of 1.22, suggesting that its stock price is 22% more volatile than the S&P 500. Comparatively, Seres Therapeutics has a beta of 2.75, suggesting that its stock price is 175% more volatile than the S&P 500.

Seres Therapeutics has a consensus target price of $73.67, suggesting a potential upside of 407.00%. Given Seres Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Seres Therapeutics is more favorable than Rein Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Rein Therapeutics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Seres Therapeutics
2 Sell rating(s)
1 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
1.75

Summary

Rein Therapeutics and Seres Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Rein Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for RNTX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RNTX vs. The Competition

MetricRein TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$31.46M$3.07B$5.70B$9.51B
Dividend YieldN/A2.36%4.69%4.01%
P/E Ratio-0.5121.0428.0720.05
Price / SalesN/A284.46448.5799.42
Price / Cash3.1742.7636.2258.56
Price / Book3.408.378.665.87
Net Income-$62.88M-$55.19M$3.25B$258.55M
7 Day Performance2.82%5.89%4.20%2.23%
1 Month Performance-5.19%17.63%10.82%12.76%
1 Year PerformanceN/A5.09%34.70%19.36%

Rein Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RNTX
Rein Therapeutics
N/A$1.46
+2.8%
N/AN/A$31.46MN/A-0.519
MCRB
Seres Therapeutics
3.5046 of 5 stars
$14.07
-0.1%
$73.67
+423.6%
-48.1%$122.95M$126.32M-3.06330Positive News
ACTU
Actuate Therapeutics
2.3621 of 5 stars
$5.76
-8.0%
$20.50
+255.9%
N/A$122.82MN/A0.0010News Coverage
TARA
Protara Therapeutics
2.1431 of 5 stars
$3.08
-1.9%
$20.50
+565.6%
+44.0%$121.15MN/A-1.7930
ONCY
Oncolytics Biotech
1.6669 of 5 stars
$1.27
-3.8%
$4.33
+241.2%
+10.7%$119.74MN/A-4.3830News Coverage
Upcoming Earnings
PLX
Protalix BioTherapeutics
2.9429 of 5 stars
$1.45
-3.3%
$15.00
+934.5%
+34.2%$115.43M$59.76M-11.15200Gap Up
SKYE
Skye Bioscience
2.523 of 5 stars
$3.89
+4.6%
$16.60
+326.7%
-32.7%$115.22MN/A-4.7411News Coverage
Gap Up
CTOR
Citius Oncology
1.6938 of 5 stars
$1.53
-4.4%
$3.00
+96.1%
N/A$114.48MN/A0.00N/APositive News
Gap Up
BHST
BioHarvest Sciences
N/A$6.92
+0.1%
$13.67
+97.5%
N/A$113.49M$25.19M-13.84N/ANews Coverage
ATOS
Atossa Genetics
3.0234 of 5 stars
$0.84
-3.2%
$6.17
+632.5%
-38.4%$112.31MN/A-4.018News Coverage
Positive News
HURA
TuHURA Biosciences
1.7927 of 5 stars
$2.62
+3.6%
$12.67
+383.5%
N/A$110.51MN/A0.00N/A

Related Companies and Tools


This page (NASDAQ:RNTX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners